TT 138

Drug Profile

TT 138

Alternative Names: MN-246; TT-138

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Mitsubishi Tanabe Pharma Corporation
  • Class Small molecules; Urologics
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Urinary frequency; Urinary incontinence

Most Recent Events

  • 18 Apr 2016 Discontinued - Phase-I for Urinary frequency in USA (PO)
  • 18 Apr 2016 Discontinued - Phase-I for Urinary incontinence in Canada (PO)
  • 18 Apr 2016 Discontinued - Phase-I for Urinary incontinence in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top